Medical Doctor Program year 2020 Source: CMS Open Payments, 2026 publication

Heliodoro Ruiz

General Practice Hialeah, FL Medical Doctor

NPI 1831529932 CMS profile 8793798

4218 E 4Th Ave, Hialeah, FL 33013

Open in the dashboard

General payments

$14

1 record reported · program year 2020

Research payments

$0

Paid to them · None reported · program year 2020

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,615,035 paid to institutions, not to them · program years 2023–2025

Through program year 2020, Heliodoro Ruiz of Hialeah, FL is reported in the CMS Open Payments database as having received $14 across 1 general payment and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $1,615,035 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 1st percentile of General Practice profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

1 row
Year Kind Relative to this record's peak year Amount Records
2020 General $14 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Heliodoro Ruiz
  • General Practice median
  • Middle half of General Practice
  • National median

In program year 2025, general payments to Heliodoro Ruiz were reported at $0. Among 4,774 General Practice profiles paid that year, the median was $106 and the middle half received between $35 and $292.

Show as a table
Year Heliodoro Ruiz General Practice median Middle half National median
2019 $0 $107 $37–$285 $163
2020 $14 $75 $25–$213 $114
2021 $0 $93 $30–$272 $132
2022 $0 $103 $36–$279 $149
2023 $0 $106 $34–$276 $160
2024 $0 $114 $39–$290 $164
2025 $0 $106 $35–$292 $169

Breakdown

Who paid General payments · program year 2020
  1. Chiesi USA, Inc. $14 1 payment

Every payment, record by record

What the payments were for General payments · program year 2020
  1. Food and Beverage $14 1 payment
Products named General payments · program year 2020
  1. KENGREAL 50MG/10ML L $14 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

287

Median for General Practice: 1,105

Drug cost

$9,322

Median for General Practice: $48,734

Branded share of claims

24.7%

Median for General Practice: 17.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Farxiga Dapagliflozin Propanediol Brand 11 $5,986
Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate Brand 11 $2,069
Atorvastatin Calcium Generic 52 $203
Levothyroxine Sodium Generic 21 $156
Omeprazole Generic 24 $152
Metoprolol Succinate Generic 22 $135
Lisinopril Generic 21 $119
Montelukast Sodium Generic 13 $105
Lisinopril-Hydrochlorothiazide Lisinopril/Hydrochlorothiazide Brand 11 $84
Losartan-Hydrochlorothiazide Losartan/Hydrochlorothiazide Brand 26 $83

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,210 Part D prescribers listed as General Practice; they describe a distribution and say nothing about conduct.

Records

1 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other General Practice in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2020

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record